Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCT-tinted is an investigational preoperative skin antiseptic developed by Becton, Dickinson and Company (BD). It is a combination of octenidine dihydrochloride, a bispyridinamine antiseptic, and isopropyl alcohol (IPA), formulated with an added colorant to facilitate visual confirmation of skin coverage during application. The product is designed to prevent surgical site infections (SSIs) by providing broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and multidrug-resistant strains. It is delivered via a single-use applicator. In a randomized, triple-masked Phase 2 clinical trial (NCT03224299), OCT-tinted was evaluated for its effectiveness in preoperative skin preparation compared to an active control (ChloraPrep) and a negative control (saline) in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on octenidine dihydrochloride + isopropyl alcohol (Becton Dickinson).